The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature.

摘要: C-erbB-2 prognostic value for survival in patients with lung cancer remains controversial. We performed a systematic review of the literature to clarify its impact. Studies were identified by an electronic search order aggregate results, after methodological assessment using scale European Lung Cancer Working Party. To be eligible, study had deal c-erbB-2 and analyse according expression. In total, 30 studies eligible: 24 dealt non-small-cell carcinoma (NSCLC), five adenocarcinoma one small-cell carcinoma. all, 31% positive c-erbB-2. According expression, 13 'negative' (significant detrimental effect on survival), 'positive' improvement) 16 not significant. Significant better subscore relative analysis results report than nonsignificant studies. 86% significant only 56% evaluable meta-analysis. This suggests possible bias our aggregated results. For NSCLC, hazard ratio was 1.55 (95% CI: 1.29-1.86) favour tumours that do express conclusion, overexpression might factor poor prognosis but there is potential overestimation risk magnitude true overexpression.